Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HEXA | P06865 | 2/20 | 0.43 |
| ▸ | HEXB | P07686 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | DHFR | P00374 | 2/20 | 0.34 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101492 | 0.88 | HEXA (0.39) | HEXAHEXBMAP4K4PIK3CDNPC1 | |
| SCHEMBL4096289 | 0.86 | HEXA (0.39) | HEXAHEXBMAP4K4TRPV3NPC1 | |
| SCHEMBL4107688 | 0.85 | HEXA (0.38) | HEXAHEXBMAP4K4TRPV3NPC1 | |
| SCHEMBL4107114 | 0.85 | HEXA (0.38) | HEXAHEXBMAP4K4TRPV3NPC1 | |
| SCHEMBL4102236 | 0.83 | PIK3CA (0.44) | PIK3CDPIK3CAMTOR | |
| SCHEMBL4105844 | 0.82 | MAP4K4 (0.39) | HEXAHEXBMAP4K4NPC1ALDH1A1 | |
| SCHEMBL4103549 | 0.82 | MAP4K4 (0.43) | HEXAHEXBMAP4K4ALDH1A1LMNA | |
| SCHEMBL4108301 | 0.81 | HEXA (0.47) | HEXAHEXBKCNH2ALDH1A1MEN1 | |
| SCHEMBL4101754 | 0.81 | MPO (0.41) | MAP4K4KCNH2HRH3PIK3CDNPC1 | |
| SCHEMBL4115427 | 0.81 | USP7 (0.43) | CYP3A4MAPK1PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | claimed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | claimed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | PNPO, PNP, DPYD | HEXA 837/4885HEXB 595/4885MAP4K4 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.